Tuberculosis in the 21st Century: Challenges in Diagnosis, Treatment, and Global Control

With an estimated 10 million cases and over one million fatalities annually, TB is still one of the most significant infectious illnesses affecting worldwide public health, mostly in low- and middle-income nations. Mainly affecting the lungs (pulmonary TB), Mycobacterium tuberculosis is a slow-growing, acid-fast bacillus that causes tuberculosis. However, it may also affect other organs, such as the lymph nodes, bones, central nervous system, and genitourinary tract. Due to a number of variables, including delayed diagnosis, poor treatment adherence, the emergence of drug-resistant strains, and socioeconomic determinants including poverty, malnutrition, and HIV co-infection, tuberculosis (TB) continues to be a major cause of morbidity and death even though it is preventable and treatable. Bacterial evasion mechanisms and the host immune response interact intricately in the pathophysiology of tuberculosis. Latent tuberculosis infection (LTBI) can result from M. tuberculosis remaining dormant in macrophages for years after inhalation. Unless they are immunocompromised, only 5–10% of infected people experience active illness at some point in their lives. Serious obstacles to tuberculosis control and eradication have arisen as a result of the development of extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB), which have further complicated treatment procedures. Although recent developments include nucleic acid amplification tests (NAATs), such as GeneXpert, and interferon gamma release assays (IGRAs) for the identification of latent infections, the diagnosis of tuberculosis still mostly depends on sputum smear microscopy, chest X-rays, and culture techniques. The necessity for novel, shorter, and more efficient medication regimens is highlighted by the fact that drug-resistant TB necessitates lengthy and sometimes hazardous second-line treatment. The BCG vaccine, early case diagnosis and treatment, and public health initiatives aimed at high-risk groups are the main components of prevention programs. Because of ongoing inequalities in health care, delayed diagnosis, and poor access to and adherence to treatment, tuberculosis eradication is still a long way off, despite international efforts through programs like the WHO's End TB Strategy.